Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Yale
•
NCI-CCC Breast Tumor Board Question
•
Breast Cancer, Non-metastatic
In light of SABCS 2022, will you use BCI to guide OFS recommendation in the adjuvant setting?
Related Questions
What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
In which situations are you comfortable with alternative dosing of ovarian suppression (e.g Lupron q3m) for premenopausal patients during adjuvant breast cancer treatment?
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
How do you manage adjuvant endocrine therapy for microinvasive HR-positive disease measuring >=1mm in extension?
Would you recommend axillary lymph node dissection in a pre-menopausal woman with ER+ PR+ HER2- IDC, s/p lumpectomy and SLN with pT1c pN1 cM0 disease, where 2 sentinel nodes are positive for macrometastasis and 1 SN is positive for micrometastasis?
Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?
What is your treatment approach in patients with early breast cancer with axillary soft tissue involvement, with or without concurrent lymph node involvement?